{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034230","form_type":"8-K","ticker":null,"cik":"0001061027","company_name":"Viracta Therapeutics, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.261437+00:00","generated_at":"2026-06-04T11:15:28.642037+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Viracta CFO/COO Dan Chevallard resigns; Melody Burcar appointed interim CFO","bullets":["Dan Chevallard resigns as CFO and COO effective March 20, 2024 to pursue other opportunities; no disagreement with company.","Melody Burcar appointed interim principal financial officer and principal accounting officer; previously SVP of Finance.","Burcar receives annual base salary of $340,000, target bonus of 35%, and stock option grant of 100,000 shares at $0.99/share.","Chevallard enters consulting agreement at $375/hour for up to 8 hours/month for up to 6 months; options/RSUs continue vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034230","json":"https://secwatch.observer/filing/0000950170-24-034230.json","markdown":"https://secwatch.observer/filing/0000950170-24-034230.md","text":"https://secwatch.observer/filing/0000950170-24-034230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/virx-20240315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:15:28.642037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"293e3dfb21","claim":"Dan Chevallard resigned as Chief Financial Officer and Chief Operating Officer at Viracta Therapeutics, Inc..","evidence_excerpt":"On March 15, 2024, Dan Chevallard informed Viracta Therapeutics, Inc. (the “Company”) that he was resigning from his positions as Chief Financial Officer and Chief Operating Officer of the Company, effective on March 20, 2024, to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"9803e08360","claim":"Melody Burcar changed role as Senior Vice President of Finance at Viracta Therapeutics, Inc..","evidence_excerpt":"Melody Burcar, MBA, CPA, 41, was promoted to the Company’s Senior Vice President of Finance, effective March 18, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Senior Vice President of Finance"}],"fact_type":"executive_change"},{"claim_id":"a23237e4a2","claim":"Melody Burcar was appointed as interim principal financial officer and interim principal accounting officer at Viracta Therapeutics, Inc..","evidence_excerpt":"Effective upon Mr. Chevallard’s resignation as Chief Financial Officer and Chief Operating Officer, Melody Burcar, the Company’s Senior Vice President of Finance, will serve as the Company’s interim principal financial officer and interim principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Chevallard.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024034230/0000950170-24-034230-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal financial officer and interim principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}